In September of 2018 the Oxford spin-off Evox Therapeutics Ltd finished their Series B financing raising £35.5 million (approximately $45.4 million) . The biotechnology company focuses on innovative therapeutics based on the capabilities of extracellular vesicles, known as exosome technology. The mission of the team is to positively impact human health worldwide. 
Exosomes are nano-sized vesicles that are found in all biological fluids and are a way that cells naturally deliver proteins and nucleic acids to other cells. By taking advantage of this technology, Evox will be able to deliver medication safely and efficiently to areas that are currently difficult or impossible to reach. This technology has the potential to revolutionise the industry. 
The proceeds from this funding round will support the research and development of exosome-based solutions, among them, several focused on rare diseases. In addition, the entity has partnerships with major pharmaceutical companies in order to fully take advantage of the developed treatments.